7 Pulmonology Headlines You Missed in August 2026

August 2026 was dominated by the interstitial lung disease (ILD) pipeline — a pair of divergent trial readouts, an FDA regulatory action, and a Fast Track designation — alongside a major bronchiectasis milestone and a timely public health reminder on COVID-19 prevention. The month's most consequential clinical data came from the phase 2b ELEVATE-IPF trial, published in the American Journal of Respiratory and Critical Care Medicine, showing that deupirfenidone (LYT-100; Celea Therapeutics) 825 mg three times daily slowed FVC decline by 91.0 mL vs placebo at 26 weeks (P =.02), with the rate of FVC decline approaching the range expected in healthy aging — a benchmark no approved or investigational idiopathic pulmonary fibrosis therapy has previously reached in a controlled trial. The ELEVATE-IPF result provides a clear phase 3 path and arrives in an IPF pipeline that received additional momentum from FDA's Fast Track designation granted August 20 to LTI-03, an inhaled Caveolin-1-derived peptide from Rein Therapeutics targeting both fibrotic signaling and alveolar epithelial repair — a dual mechanism that, if validated, would distinguish it from existing antifibrotics.

Counterbalancing the positive IPF signals, pamufetinib — an oral multikinase inhibitor evaluated in progressive fibrosing ILD — failed to slow FVC decline vs continued nintedanib or pirfenidone in a phase 2b trial, with FVC declines of -157.8 mL (100 mg) and -96.0 mL (50 mg) vs -63.6 mL in the control arm, alongside greater DLCO decline and higher acute exacerbation rates on the investigational agent.

Beyond ILD, August brought significant movement in pulmonary vascular disease and a pivotal bronchiectasis milestone. The FDA accepted United Therapeutics' NDA for ralinepag in pulmonary arterial hypertension on August 24, with a PDUFA date of June 24, 2027 — a consequential filing for the first high-potency oral prostacyclin receptor agonist, backed by the phase 3 ADVANCE OUTCOMES trial showing a 55% reduction in clinical worsening vs placebo. On the 1-year anniversary of brensocatib's August 12, 2025, approval for non-CF bronchiectasis, 2 prescribing pulmonologists described a field transformed — with most patients reporting subjective improvements in cough and sputum clearance, a tolerability profile holding up better than initially feared, and a real-world prescribing experience that continues to raise questions about which patients benefit most and how the drug performs alongside common comorbid infections.

In pulmonary sarcoidosis, namilumab — an investigational anti-GM-CSF monoclonal antibody — failed its primary endpoint in the phase 2 RESOLVE-Lung trial, with rescue events occurring in 37.5% of namilumab-treated patients vs 23.5% of placebo-treated patients over 26 weeks, leaving the condition without an approved targeted therapy. Juanita Mora, MD, closed out August's coverage with an American Lung Association COVID-19 prevention campaign interview, noting that only 18% of adults received a COVID-19 vaccine in the 2025–26 respiratory season despite twice-yearly circulation patterns and approximately 6-month waning immunity, and urging pulmonologists to counsel high-risk patients on summer boosting and the underused antiviral prophylaxis option.

Check out this August 2026 pulmonology month in review for full coverage of these stories and more.

1. One Year Later: How Brensocatib Has Changed Bronchiectasis Care

One year after the FDA approved brensocatib (Brinsupri; Insmed) as the first disease-modifying therapy for non-CF bronchiectasis — based on phase 3 ASPEN trial data showing 20% reductions in annualized exacerbation rates at both doses vs placebo and a 38 mL slowing of FVC decline at 25 mg over 12 months — Mark L. Metersky, MD, of UConn Health and Ashwin Basavaraj, MD, of NYU Langone described a field with a genuine first-in-class treatment and real-world prescribing experience accumulating. Tolerability, including skin changes involving thickening behind the knees, elbows, and hands, has been limited and has not deterred uptake; both physicians noted that patients who followed the drug's development before approval have responded well. Outstanding questions include how brensocatib performs in patients with concurrent nontuberculous mycobacteria infection — present in roughly half of US bronchiectasis patients — and how its early real-world safety profile holds up over longer-term follow-up.

2. FDA Fast Tracks LTI-03 for Idiopathic Pulmonary Fibrosis

The FDA granted Fast Track designation on August 20, 2026, to LTI-03 (Rein Therapeutics), an inhaled Caveolin-1-scaffolding-protein-derived peptide being evaluated in the phase 2 RENEW trial in IPF. LTI-03's mechanism targets fibrotic signaling while aiming to preserve and restore alveolar epithelial progenitor populations — a reparative approach that, if validated, would distinguish it mechanistically from both pirfenidone and nintedanib, which slow progression without restoring lung architecture. The Fast Track designation follows prior Orphan Drug status; RENEW is enrolling approximately 120 patients across five countries with interim safety and FVC change data anticipated in the second half of 2026.

3. Deupirfenidone Slows FVC Decline in Phase 2b IPF Trial

Deupirfenidone (LYT-100; Celea Therapeutics), a deuterium-modified form of pirfenidone designed to improve tolerability by reducing CYP1A2-mediated metabolism, slowed FVC decline by 91.0 mL vs placebo at 26 weeks in the phase 2b ELEVATE-IPF trial (P =.02), with the 825 mg three-times-daily arm achieving a rate of decline (-21.5 mL) approaching the range expected in healthy older adults. ELEVATE-IPF was the first IPF trial to include an active standard-of-care comparator alongside placebo — pirfenidone 801 mg TID, which produced -51.6 mL — providing context that positions deupirfenidone's effect size approximately 50% larger than the active comparator's. Progression delay was also significant (HR, 0.439; P =.0023), and Celea Therapeutics is advancing toward the phase 3 SURPASS-IPF trial.

4. Pamufetinib Fails to Slow FVC Decline in Progressive Fibrosing ILD

Pamufetinib (TAS-115), an oral multikinase inhibitor targeting VEGFR, FGFR, MET, AXL, and Src, failed to slow FVC decline vs continued nintedanib or pirfenidone in 243 patients with progressive CF-ILD in a 41-site, double-dummy phase 2b trial — with 26-week FVC declines of -157.8 mL and -96.0 mL at the 100 mg and 50 mg doses vs -63.6 mL in the control arm. Secondary outcomes favored the control arm, including greater DLCO decline and higher acute exacerbation rates on pamufetinib; deaths were numerically higher in the pamufetinib arms, though the trial was underpowered for mortality inference. Investigators hypothesized that off-target MET/AXL/Src inhibition may have impaired alveolar epithelial repair, consistent with an early FVC suppression that reversed after week 16.

5. FDA Accepts NDA for Ralinepag in Pulmonary Arterial Hypertension

The FDA accepted United Therapeutics' NDA for ralinepag, an investigational once-daily oral prostacyclin receptor agonist, for pulmonary arterial hypertension on August 24, 2026, with a PDUFA target action date of June 24, 2027. The application is based on the phase 3 ADVANCE OUTCOMES trial in 687 PAH patients on background therapy, which demonstrated a 55% reduction in time to adjudicated clinical worsening — including hospitalization, escalation to parenteral prostacyclin therapy, disease progression, or death — at individualized doses without a prespecified ceiling. The acceptance moves the first high-potency oral IP receptor agonist into FDA review in a class currently represented only by selexipag, which carries a fixed-dose ceiling.

6. Namilumab Fails Primary End Point in Pulmonary Sarcoidosis

Namilumab, an investigational subcutaneous anti-GM-CSF monoclonal antibody, failed its primary endpoint in the phase 2 RESOLVE-Lung trial, with rescue events — defined as clinically significant worsening requiring treatment escalation — occurring in 37.5% of namilumab-treated patients vs 23.5% of placebo-treated patients over 26 weeks in 107 patients with chronic active pulmonary sarcoidosis. The trial required FDG-PET/CT evidence of active disease and mandated a corticosteroid taper to 5 mg/day or less by week 6 or 10, a design that may have increased worsening risk in the treatment arm during the tapering window. The result leaves pulmonary sarcoidosis without an approved targeted therapy; current management relies on corticosteroids and off-label immunosuppression with methotrexate or similar agents.

7. ALA: Why COVID-19 Boosters Matter Now, With Juanita Mora, MD

In an interview tied to the American Lung Association's COVID-19 prevention campaign, allergist Juanita Mora, MD, of Chicago Allergy Center, reported that only 18% of adults received a COVID-19 vaccine during the 2025–26 respiratory virus season — a figure that rose to 31% among adults aged 65–74 and 37% among those 75 and older, the groups at greatest risk for severe disease. Mora described COVID-19 as having settled into a predictable twice-yearly circulation pattern with approximately 6-month waning of antibody protection, supporting summer boosting for high-risk patients including those aged 65 and older and those with chronic lung disease, heart disease, kidney disease, diabetes, or immunocompromise. Antiviral use remains below 15% and timely initiation within the 5-day window only 16%, gaps she said pulmonologists are well positioned to close through patient counseling and provider-level advocacy.